Article

FDA Approves Absorbable Stent

Author(s):

The FDA approved the first fully absorbable stent to treat coronary artery disease.

The US Food and Drug Administration (FDA) today approved the first fully absorbable drug-eluting stent.

The device Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) is made by Abbott Vascular in Santa Clara, CA.

The stent offers a new option for patients with coronary artery disease, though it had slightly higher rates of undesirable side effects that the metallic stent used in comparison in clinical trials.

It elutes everolimus and is made from a biodegradable polymer known as poly(L-lactide) similar to that used in absorbable sutures, the FDA noted.

As it is absorbed, "the body gradually eliminates the presence of foreign material in the artery once the stent is no longer needed."

Four small platinum markers remain at the placement site to guide cardiologists later should they need to know where it was.

Data leading to its approval came from a randomized trial of 2,008 patients which compared the device to a drug-eluting metallic stent.

At one year the Absorb GT1 device patients had major adverse cardiac events at a rate of 7.8% compared to 6.1% of controls.

Those patients also had somewhat higher rates of blood clots forming within the device at 1.54% compared to 0.74% for controls.

It is contraindicated for patients with allergies to everolimus or the materials used in the device. Patients must be able to tolerate long term therapy with aspirin or other blood thinners.

Related Videos
Experts' Perspectives: Top Stories in Cardiology for 2024
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
© 2025 MJH Life Sciences

All rights reserved.